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ABSTRACT
Primary herpetic gingivostomatitis (PHGS) represents the clinically apparent pattern of primary herpes
simplex virus (HSV) infection, since the vast majority of other primary infections are symptomless.
PHGS is caused predominantly by HSV-1 and affects mainly children. Prodromal symptoms, such as
fever, anorexia, irritability, malaise and headache, may occur in advance of disease. The disease presents
as numerous pin-head vesicles, which rupture rapidly to form painful irregular ulcerations covered by
yellow–grey membranes. Sub-mandibular lymphadenitis, halitosis and refusal to drink are usual
concomitant findings. Following resolution of the lesions, the virus travels through the nerve endings to
the nerve cells serving the affected area, whereupon it enters a latent state. When the host becomes
stressed, the virus replicates and migrates in skin, mucosae and, in rare instances, the central nervous
system. A range of morbidities, or even mortality, may then occur, i.e., recurrent HSV infections, which
are directly or indirectly associated with PHGS. These pathological entities range from the innocuous
herpes labialis to life-threatening meningoencephalitis.
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INTRODUCTION
Primary herpetic gingivostomatitis (PHGS) repre-
sents the most commonly observed clinical mani-
festation of primary herpes simplex virus (HSV)
infection, occurring in 25–30% of affected chil-
dren [1]. Approximately 90% of cases are caused
by HSV-1, although detection of HSV-2 has also
been reported. The overwhelming majority of
primary HSV infections are asymptomatic, so that
PHGS is considered the exception rather than the
rule. Indeed, in a study of 4000 children seropos-
itive for HSV-1, only 12% had evident signs and
symptoms of infection [2,3].
Epidemiologically, there are two peaks with
respect to the age at which PHGS occurs. The first
peak occurs in children aged between 6 months
and 5 years, and the second peak occurs in young
adults in their early 20s [4]. In rare cases, PHGS
can occur in neonates, in adults, and even in the
elderly [5–7]. Geographical location and socio-
economic status also influence the incidence of
HSV-1 infections. Hence, individuals in develop-
ing countries with a lower socio-economic status
become seropositive for HSV-1 at an earlier age
than their counterparts in developed countries [8].
CLINICAL SYMPTOMS
In terms of pathology, it is accepted generally that
HSV-1 gains access through disruptions of skin
integrity or mucous membranes. This procedure
is mediated via ligand–receptor interactions (see
below). Following an incubation period of
1–26 days, prodromal, non-pathognomonic signs
and symptoms occur, including fever, chills,
nausea, anorexia, irritability, malaise and head-
ache [3,9–11]. The onset of the acute phase is
abrupt, and is usually accompanied by pain in the
mouth, salivation, fetor oris, refusal to drink and
sub-mandibular lymphadenitis [12]. The affected
mucosa develops numerous pin-head vesicles
(rarely seen), which break down rapidly to
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produce numerous small, red lesions. These
initial lesions enlarge slightly and develop central
ulcerations covered by yellow–grey membranes.
Adjacent lesions may coalesce to form irregular
ulcerations. Lesions may involve buccal mucosa,
tongue, posterior pharynx, and any gingival and
palatal mucosae. Moreover, the affected gingivae
often exhibit discernible erosions along the mid-
facial free gingival margins, and these may
precede the appearance of the mucosal vesicles
[3,12]. Finally, lesions localised to the vermilion
and the adjacent perioral skin are not uncommon.
Mild lesions usually heal within 5–7 days with-
out scar formation, but healing may require
2–3 weeks in severe cases [3,10,13–16]. It has been
postulated that PHGS is the clinical pattern of the
primary HSV infection occurring in children,
whereas pharyngotonsillitis, or mononucleosis-
like disease, is the primary HSV infection in
adults [3].
LATENCY AND REACTIVATION OF
HSV
Before discussing the potential after-effects of
PHGS, it is relevant to consider briefly the
structure and pathogenesis of HSV (for a detailed
review, see Roizman and Knipe [17]). The unique
biological properties of these viruses are their
neurotropism and their ability to remain latent in
nerve and ganglial cells [2,18]. Their proclivity to
reside in neural immune-privileged tissues, and
subsequently to elude the immune system ‘recon-
naissance’, is explained by the following facts:
(1) the shielding of central nervous system (CNS)
and peripheral nervous system by the blood–
brain barrier and blood–nerve barrier; (2) the non-
expression of the typical major histocompatibility
complex class I; (3) the absence of regular lym-
phoid drainage; and (4) the lack of intra-neural
lymphatic channels [19,20]. It is also known that
the viral protein ICP47 contributes to immuno-
evasion by inhibiting binding of viral peptides to
TAP, a molecule necessary for major histocom-
patibility complex class I molecule presentation
[20]. In addition, the viral infection protein ICP0,
amongst other roles, enhances HSV resistance to
interferon-a ⁄ b (IFN-a ⁄ b) [21].
HSV belongs to the a-herpesvirinae family. It
has been demonstrated that there are two distinct
serotypes, referred to as HSV-1 and HSV-2 [17].
Both are double-stranded DNA viruses and they
have 50% homology. The HSV genome is 152 kb
in size, with an unmethylated G + C content of
68% for HSV-1 and 69% for HSV-2 [22–24].
In broad terms, HSV-1 is responsible for HSV
infections encountered above the waist, while
HSV-2 is isolated from HSV infections below the
waist, although exceptions can occur [5]. It is also
believed that HSV-1 emulates HSV-2, inasmuch
as individuals seropositive for HSV-1 are less
susceptible to disease caused by HSV-2 [8,25].
The HSV virion comprises four elements: (1) a
core, accommodating the viral DNA; (2) an
icosadeltahedral capsid surrounding the core;
(3) a tegument; and (4) an outer envelope with
projecting spikes [17]. The envelope surrounds
the capsid–tegument structure, and consists of
glycosylated (gB, gD, gE, gG, gH, gI, gK, gL, gM
and gJ) and several non-glycosylated (UL24, US9
and, possibly, UL24, UL43 and UL34) viral pro-
teins, lipids, and polyamines (spermine and sper-
midine). Host immune responses are greatest
against the structural proteins and the envelope
glycoproteins [17,26]. The tegument contains sev-
eral proteins, namely VP16, VP11–12, VP13–14,
the virion host shut-off (vhs) protein, VP1–2 and
the product of gene Us11 [17].
There are three discernable forms of capsid
morphology, distinguishable by the distance sed-
imented in sucrose gradients [27]. ‘A’ capsids are
empty, containing neither DNA nor scaffold
proteins. These are thought to be capsids for
which the DNA packaging process failed. ‘B’
capsids are devoid of DNA, but contain the
scaffold proteins. ‘C’ capsids, which sediment
furthest, contain virus DNA and are the capsids
that mature into infectious virions. A fourth
capsid type, which cannot be isolated from
sucrose gradients, but has been observed by
ultrastructural analysis of infected cells, is the
procapsid, which is thought to be the earliest
spherical structure formed in HSV-1-infected cells
[17,27].
Finally, the 152-kb double-stranded DNA of
HSV exists in three forms: linear, circular or
concatemeric, depending on the stage in the virus
replication cycle. ICP0 seems to regulate this
process [28,29].
The replication cycle for HSV includes: (1) entry
into epithelial cells; (2) replication in epithelial
cells and release with concomitant cell lysis
(clinically seen as PHGS); (3) entry into the nerve
that serves the affected area and transport to cell
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nuclei (the trigeminal ganglion for PHGS, but
superior cervical, sphenopalatine, vestibular or
geniculate ganglia may also be affected) [18,30–
33]; and (4) latency or reactivation with antero-
grade axonal transport and manifestation of
recurrent HSV lesions in skin and, rarely, in the
CNS [2].
Entry of the virus into the cell is a three-step
process. First, HSV attaches, mainly via gC, but
also via gB, to the cell (epithelial, epidermis and
neural) surface heparan sulphate [34,35]. HSV
then binds to co-receptors belonging to the
immunoglobulin superfamily, namely nectins 1a
and 1b, previously called herpes virus entry
mediators C (HveC) and herpes virus immuno-
globulin-like receptor (HIgR), respectively [36].
The C-terminal domains of these receptors bind to
L-afadin, a PDZ-binding protein (PDZ is the
acronym of the PSD-95 ⁄Dlg ⁄ZO-1 protein do-
main) that anchors these molecules to cytoskele-
ton actin and adherens junctions, thus facilitating
cell-to-cell propagation of HSV in skin, brain and
ganglia [17,37,38]. However, nectins also facilitate
the ingress of HSV into cells, and some fraction of
nectins must therefore also be distributed on the
apical surfaces of polarised cells [39]. Tran et al.
[40] consider that gG is an essential molecule for
virus entry through the apical surfaces of polar-
ised cells, i.e., keratinocytes and neurones. Man-
nose-6-phosphate receptors can also act as HSV
receptors [41]. The third stage of virus entry
comprises the fusion of the virus envelope with
the cell membrane, a process referred to as de-
envelopment. Virus–cell fusion requires the par-
ticipation of gD, gB and the gH–gL heterodimer
[17]. Overall, attachment to the apical surface of
polarised cells is gC-dependent, whereas ingress
through the basolateral facet (required for cell-to-
cell spread as well as entry into cells after
reactivation) is gC-independent. In addition, gG
plays a pivotal role in post-attachment entry on
the apical surface, but is not essential for basolat-
eral entry.
Following fusion, the capsid, together with the
associated tegument proteins, travels throughout
the cytoplasm, and then virus DNA is released
into the nucleus. Replication of HSV takes place
and, following assembly of the virions and pack-
aging of DNA, cell lysis ensues [17]. This phe-
nomenon is seen clinically as PHGS. It is of note
that virions shed into the saliva can travel to other
parts of the body, or can contaminate other
individuals via airborne or waterborne spread
[11,42].
With respect to the fate of the newly formed
virions, Scott et al. [43] have reviewed the oral
shedding of HSV-1. Hill and Blyth [44] developed
the ‘skin trigger’ theory, which was supported by
the work of Hochman et al. [45]. According to this
theory, the oral cavity may be a reservoir of latent
HSV, which is guarded by the immune system.
Support for this theory comes from the rapid
development of recurrent herpetic lesions, and
the fact that herpes antigens could be detected in
the sulcular gingival epithelium of 60% of indi-
viduals with otherwise healthy gingiva.
It is accepted universally that HSV epithelial
replication is followed by transport of virus to the
trigeminal or other ganglia. Thus, the newly
formed virions enter the neuronal processes of
the nerve that serves the infected region. This
process is akin to the one described above.
Transport of the de-enveloped virions to the
trigeminal ganglion, at 3–5 mm ⁄h, is accom-
plished via the microtubules of the neu-
rones. Moreover, UL34 viral protein binds to the
N-terminal domain of the 1a intermediate chain
of the cytoplasmic neuronal dynein, and uses the
microtubular network for retrograde transport of
the capsid–tegument structure to the nuclear pore
[46,47]. Although actin filaments and kinesins are
now known to act as tracks for axoplasmic
organelle motility, their role in retrograde axial
transport has yet to be elucidated [46]. Once the
capsid reaches the nuclear pore, an interaction
between the capsid and nuclear pore complex
takes place. It seems that the capsid, particularly
the VP1–2 tegument protein, has nuclear locali-
sation sequences that form a complex with nuc-
lear localisation sequence receptors, i.e., importins
or karyopherins [17,48]. Three putative mecha-
nisms have been implicated in the transport of
virus DNA into the nucleus [48].
The fate of HSV following entry into the
nucleus is determined by virus and host immune
system responses, but latency is established in the
vast majority of cases. During latency, only
latency-associated transcripts (LATs) are present
in the nucleus, although low levels of lytic viral
gene mRNAs have also been detected [49–51].
Theil et al. [19] demonstrated that the latter may
trigger a chronic inflammatory response, inclu-
ding CD8+ T-cells, CD68+ macrophages, natural
killer cells, and interleukins IFN-c and tumour
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necrosis factor-a, which are attracted by the
chemokines RANTES and IP-10 [19,52,53].
Mogensen et al. [54] showed that the activation
of macrophages results from mitochondrial stress,
with subsequent nuclear factor kappa B activation
inducing development of a Th1 response by
releasing interleukin-12 [20,54,55]. It has also been
postulated that the immune system adopts a non-
cytolytic profile during latency rather than a lytic
profile, and that IFN-c can prevent HSV reactiva-
tion from latency [56]. On the other hand, HSV
tries to prolong its stay in the cell nucleus by
adopting mechanisms of immuno-evasion and
neuronal survival. Two models by which this
can be accomplished have been suggested. The
first suggests that LATs downregulate virus
expression; hence, the viruses escape from
immunosurveillance [48,57]. The second suggests
that LATs possess anti-apoptotic properties.
Moreover, the 2.0-kb LAT intron inhibits both
exogenous caspase-8 (rendering the neural cells
refractory to IFN-c, tumour necrosis factor-a and
T-cell granzymes B) and endogenous mitochond-
rial caspase-9 apoptotic pathways [33,48,58,59]. It
should be noted that ICP4, ICP27, viral glycopro-
teins gD and gJ and protein kinase Us3 also have
anti-apoptotic properties [17].
Reactivation of the virus and re-initiation of the
productive cycle may sometimes occur spontane-
ously, but this is more often secondary to infec-
tion with human immunodeficiency virus, cancer,
exposure to UV light, organ transplantation,
pregnancy or menstruation, fever, cold, X-ray
irradiation, chemotherapy, fractures, tooth extrac-
tion, sideropenia, gastrointestinal upset, surgery
or other stress-inducing states [4,43,60,61]. More-
over, it is believed that human immunodeficiency
virus enhances HSV virulence, and vice versa
[8,62]. Cancer induces HSV reactivation by alter-
ing immune responses from Th1 to Th2 [63]. The
same alteration results from exposure of kera-
tinocytes to UV light, through release of interleu-
kin-10. The latter can downregulate Th1
responses, thus facilitating the development of
Th2 responses [64]. In all other cases, HSV
reactivation may be a consequence of corticoster-
oid and adrenaline release caused by stress-
inducing stimuli [65]. Finally, the 5¢ exon of LAT
has been implicated in HSV reactivation, although
Thomas et al. [66,67] proposed that the 2.0-kb
intron region of the LAT open reading frame is
responsible for HSV-1 reactivation [33,49]. In
addition, Halford and Schaffer [68] have
demonstrated that ICP0 is required for HSV
reactivation.
During lytic infection with HSV, virus genes
are expressed in a cascade-like fashion, including
the transcription of initiator element genes,
followed by transcription of the early genes,
replication of virus DNA and, finally, transcrip-
tion of the late genes, although the transcription
of some late genes, referred to as b1 genes,
occurs before DNA replication [69]. Transcription
of initiator element genes is stimulated by VP16,
a tegument protein that is transported into the
nucleus, with positive and negative feedback
loops [17,70]. Both transcription and replication
are performed in the cell nucleus, whereas
translation is carried out in the endoplasmic
reticulum. The completion of these processes
implies either the usurpation–recruitment of
host-cell mechanisms or the inhibition–abroga-
tion of others. Hence, the vhs protein shuts down
host protein production and coordinates viral
gene expression, whereas the c34.5 gene product
and the Us10–12 gene products block protein
synthesis by inhibiting protein kinase R [71].
Likewise, HSV recruits host-cell RNA polym-
erase II for viral gene expression [17]. Once the
early genes are expressed, several of these
proteins are aggregated into the nucleus and
assemble on parental virus DNA molecules, in
structures termed pre-replicative sites, close to
nuclear domain 10, the domain where virus
DNA replication takes place [17].
Tang et al. [72] demonstrated that ICP24–ICP27
interaction plays a key role in localisation of virus
DNA to nuclear domain 10. Virus DNA replica-
tion is accomplished by viral (DNA polymerase,
accessory protein, origin-binding protein, the
ICP8 single-stranded DNA-binding protein and
the helicase-primase proteins) and host-cell (DNA
polymerase a-primase, DNA ligase and topo-
isomerase II) enzymes in the replicative site at
nuclear domain 10 [17,73]. DNA replication is
followed by capsid assembly: initially procapsid,
and eventually capsid B, formation. After DNA
cleavage and packaging, encapsidation of virus
DNA, or insertion into capsid B, takes place. Virus
DNA enters through a portal, whereas scaffolding
proteins are extracted, resulting in capsid C
formation [17,27,74–77]. These processes, along
with other cellular events, produce the character-
istic appearance of the so-called intra-nuclear
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inclusion bodies seen under the light microscope
[17]. The fully formed virion leaves the nucleus
and travels through the cytosol to the nerve
endings, which in turn lead to skin or mucosa,
and rarely to the CNS. The replication of HSV is
accompanied by nerve cell death [78].
COMPLICATIONS AND RECURRENT
INFECTIONS
The complications of PHGS range from indolent
cold sores to life-threatening encephalitis. The
most common cause of morbidity following
PHGS is dehydration. Amir et al. [1] found that
89% of patients drank less than normal, and that
two of 36 patients were unable to drink. In severe
cases, hospitalisation and parenteral fluid intake
are recommended. Bacteraemia caused by the
Gram-negative bacillus Kingella kingae has been
observed [1,79], but this complication subsided
uneventfully after the administration of antibiot-
ics.
An innocuous morbidity of PHGS is herpes
labialis (also known as ‘cold sores’ or ‘fever
blister’). This represents the most common mani-
festation of HSV reactivation in trigeminal gan-
glia, with an incidence among adults of 20–40%
[80]. Two or three recurrences annually are
normal, but as many as 12 may occur. HSV-1
infections recur more often than HSV-2 infections.
The vermilion border and adjacent skin of the lips
are the sites affected most frequently, although
the skin of the nose, chin or cheek may also be
involved. Pain, tingling, burning sensation, itch-
ing, fever (fever blisters) or upper respiratory
tract infection (cold sores) usually precede the
onset of the disease [3,81]. Herpes labialis is
characterised by multiple small, erythematous
papules that develop and form clusters of fluid-
filled vesicles that rupture within 2 days. The
total area involved is usually less than 100 mm2,
and the lesions progress to being pustular or
ulcerative, with crusting within 3–4 days [5]. Pain
is intense at the outset, but resolves over 4–5 days.
Shedding of virus from lesions continues, with
progressive healing over 2–3 days. Healing is
rapid and is complete within 10 days. Remission
of herpes labialis can occur; inciting factors are
fever, stress and exposure to UV light [5].
‘Herpetic geometric glossitis’, characterised by
linear fissures on the dorsum of the tongue, with
branching dendritic lesions, represents an HSV-1
infection in immunocompromised patients [82],
whereas recurrent herpetic stomatitis presents in
immunocompetent individuals. The latter differs
from PHGS in that it has a more confined
enanthema. Tabaee et al. [83] described an oral
recurrent HSV infection presenting as an im-
mense tongue mass in a patient who underwent
cardiac transplantation. Paradoxically, this lesion
was first encountered 10 months after transplan-
tation, although most recurrent oral HSV infec-
tions occur within the first month post-transplant
[83,84]. The lesion was initially considered to be a
squamous carcinoma, so a 0.5-cm free margin
excision was performed. Later, following immuno-
staining, the final diagnosis of HSV infection was
established [83].
An even more unusual clinical entity is a
recrudescent HSV infection identical to PHGS.
Use of laboratory screening tests is mandatory in
such cases in order to make the differential
diagnosis [85].
Finally, there is a single report [60] postulating
that recurrent HSV infection affecting the oral
cavity may even manifest as a dry socket, since
HSV was isolated from the socket. However, there
are reservations concerning the acceptance of this
pathology.
A less common presentation of HSV is herpetic
whitlow (herpetic paronychia). This may occur as
a result of auto-inoculation in children with
orofacial herpes (i.e., children sucking their
hands), and in adults in association with genital
herpes [3,86]. In the past, before the use of
protective gloves, dental personnel could come
into contact with HSV during the treatment of
patients suffering from HSV infection. Whitlow is
a noxious pathology characterised by prodromal
symptoms, namely pain and burning, during the
2–20-day incubation period. Herpetic whitlow
usually manifests with local swelling, erythema,
and one or more small, tender vesicles. Fever and
malaise may be present, especially in infants. The
lesions typically contain clear fluid in the initial
stages, but the fluid can become cloudy after a
week by virtue of the presence of white blood
cells. In contrast, bacterial paronychia presents
with suppuration from the onset of the disease.
The site affected most commonly is the digital
pulp space, but infections of the nail folds or
lateral aspects of the fingers can also be encoun-
tered. The disease subsides completely within
3 weeks [87].
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Another dermatosis caused by HSV is herpes
gladiatorum or ‘scrumpox’. This usually affects
individuals participating in contact sports, e.g.,
wrestling or rugby football, or parents who have
kissed areas of dermatological injury in children
[3,80].
Eczema herpeticum (also known as Kaposi’s
varicelliform eruption) is a skin infection affecting
children and adults, in which HSV is implicated.
Habif [81] considers that eczema herpeticum is an
association of atopic dermatitis with HSV infec-
tion. The disease is most common in areas of
active or recently healed atopic dermatitis, par-
ticularly on the face, but it can also develop in
areas with pre-existing dermatoses, such as are
seen in atopic dermatitis, Darier’s disease, myco-
sis fungoides, pemphigus folliaceous and Sezary’s
syndrome, and even on normal skin. In one-third
of paediatric patients with eczema herpeticum,
there is a history of herpes labialis in a parent. The
disease is characterised by the eruption of numer-
ous vesicles, which gradually become pustular,
and finally are rendered umbilicated. New groups
of vesicles may appear during the following
weeks. High fever and adenopathy become
apparent 2–3 days after the eruption of vesicles.
The fever resolves in 4–5 days in uncomplicated
cases, and the lesions evolve in the typical
manner. The prognosis is usually good, but the
patient may succumb when viraemia occurs along
with visceral involvement [8,81].
Erythema multiform is another dermatosis in
which HSV is implicated. Indeed, HSV may
precede erythema multiform, and post-herpetic
erythema multiform is thought to be the sequel of
perivascular immune complex deposition of
immunoglobulin, herpes virus antigen and com-
plement [88].
An even more severe complication of PHGS is
ocular involvement. This can be caused by auto-
inoculation from PHGS or herpes labialis, or via
the nerve route [5,17,89]. HSV infection of the eye
is the most frequent cause of corneal blindness in
the USA [17]. Herpetic keratoconjunctivitis is
associated with acute onset of pain, blurring of
vision, characteristic dendritic lesions of the cor-
nea, injection, chemosis, photophobia, lacrimation
and eyelid oedema. Less commonly, advanced
disease can result in ‘geographical’ or ‘amoeboid’
ulcer of the cornea. The visual acuity declines in
the presence of the ulcers after several bouts of
infection and, with progressive stromal involve-
ment, opacification of the cornea may occur.
Repeated individual attacks may take place for
several weeks or even months. Progressive dis-
ease can result in visual loss or even rupture of
the globe [5,89].
Herpetic stromal keratitis caused by HSV
appears to be related to T-cell-dependent destruc-
tion of deep corneal tissue. The UL6 viral protein
mimics the corneal antigens, so an autoreaction
with corneal antigens targeting T-cells has been
postulated to be a factor in this infection [90].
Recently, Lundberg et al. [24] proposed a model
for herpetic stromal keratitis pathogenesis in
which the unmethylated CpG dinucleotides,
released by degenerate stromal cells infected
previously by HSV, bind to Toll-like receptor 9
of macrophages, which in turn orchestrate the
Th1 response with release of cytokines and
recruitment of autoreactive T-cells [24].
Herpetic oesophagitis and herpetic infection of
the lower respiratory tract may result from direct
extension of oropharyngeal infection, including
PHGS [18]. The former may also represent the
consequence of de-novo reactivation of HSV and
propagation to the oesophageal mucosa via the
vagus nerve. HSV oesophagitis may manifest even
in immunocompetent patients, but it is more likely
to occur in patients who have undergone kidney
or liver transplantation, or in patients suffering
from AIDS. The predominant symptoms of HSV
oesophagitis are odynophagia, dysphagia, subs-
ternal pain and weight loss, while bleeding or
even stricture formation may complicate the dis-
ease [91]. Clinically, there are multiple oval ulcer-
ations on an erythematous base, which may or
may not have a patchy white pseudomembrane.
The distal oesophagus is involved most com-
monly, although disseminated disease may occur
when the immune system is deranged [18,92].
HSV pneumonitis is uncommon unless an
individual is immunocompromised, and may
result from extension of herpetic tracheobronch-
itis into lung parenchyma, whereupon focal
necrotising pneumonitis usually ensues. The mor-
tality rate in immunosuppressed patients is high
(>80%) [18]. Bogger-Goren [93] reported a case of
acute epiglottitis in a child aged 16 months that
was caused by HSV, and involvement of the
peripheral nervous system or the spinal cord may
also be complications resulting from PHGS.
Nasatzky and Katz [94] reported a case of Bell’s
palsy associated with HSV gingivostomatitis. It
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has been postulated that Bell’s palsy results from
the replication of HSV in geniculate ganglia, and
that axonal spread and multiplication of the
reactivated virus leads to inflammation, demyeli-
nation and palsy, which usually resolve within
6–8 weeks, although sequelae may occur in some
patients. It has also been suggested that the
anatomical structure of the Fallopian canal may
be responsible for nerve compression secondary
to oedema, which can lead finally to nerve
degeneration and severe facial paralysis.
Galanakis et al. [95] reported a case of trans-
verse myelitis associated with PHGS in which the
patient exhibited the typical signs and symptoms
of transverse myelitis, such as acute weakness,
acute pain in the lower extremities, lower back
and abdomen, weak leg muscles and bladder
dysfunction, but retained deep sensation. The
patient’s history revealed that he had suffered
from herpetic gingivostomatitis, and lumbar
puncture, magnetic resonance imaging and sero-
logy were all consistent with transverse myelitis
caused by HSV-1.
Herpetic meningoencephalitis is the most fatal
complication of HSV infection. In general, herp-
etic encephalitis (HSE) is attributed mainly to
HSV-1, whereas meningitis is ascribed to HSV-2
[96]. HSE is considered to be the most common
cause of sporadic, fatal encephalitis in the USA,
and probably worldwide, as it accounts for
10–20% of all cases of viral encephalitis [97,98],
either primary or secondary. There are three
patterns of viral propagation to brain paren-
chyma: (1) exogenously acquired virus entering
the CNS via the olfactory epithelium and olfac-
tory bulb; (2) reactivation of latent HSV in
ganglia, followed by spread via trigeminal and
autonomous nerve roots; and (3) blood-borne
spread, especially in neonates or immunocom-
promised individuals [5,18]. However, only Ito
et al. [97] have reported HSE associated directly
with PHGS. The clinical signs and symptoms of
HSE depend on the location of the lesion. Typic-
ally, HSE produces focal haemorrhagic necrosis of
temporal and frontal lobe structures, including
limbic mesocortices, amygdala and hippocampus,
although the involvement of other sites cannot be
excluded [2,98–102]. The clinical hallmark of HSE
is the triad of fever, headache and altered con-
sciousness [103]. Concomitant signs and symp-
toms include confusion, lethargy, seizures and
mental aberrations, but other symptoms may also
become apparent, depending on the location of
the lesion [99]. The presence of neurological
symptoms, e.g., altered sensorium or other focal
neurological findings, distinguish HSE from HSV
meningitis [103]. Mortality rates reach 60–70%
and, even after adequate medication, permanent
neurological deficits will remain, with only 2.5%
of surviving patients recovering normal neuro-
logical function [98,104].
In terms of pathogenesis, it should be empha-
sised that, although HSE has been associated with
necrotic cell death resulting from virus replication
and inflammatory changes ⁄ cerebral oedema sec-
ondary to the virus-induced immune response,
the role of virus-induced nerve cell apoptosis
should not be overlooked [98,105]. Indeed,
Perkins et al. [98] demonstrated HSV-1-induced
apoptosis mediated by c-jun N-terminal kinase.
Likewise, Anglen et al. [65] showed that CD8+ T-
cells, which are probably the most efficient cell
population active against HSV, may enhance or
eliminate brain injury when they infiltrate brain
tissues before or after HSV infection, respectively.
In contrast, meningitis is ascribed generally to
HSV-2. Headache, asthenia, high fever, neck stiff-
ness, nausea ⁄vomiting, photophobia, muscle pain
and radiculalgia are some of the symptoms indic-
ative of meningitis [106]. Mommeja-Marin et al.
[106] reported no cases of visceral involvement,
and considered that meningitis did not result from
blood-borne spread of viraemia, but probably from
spread through the nerve tract, starting from sacral
ganglia. Cerebrospinal fluid analysis is suggestive
of viral meningitis if high levels of white blood
cells, especially lymphocytes (lymphocytic pleocy-
tosis), are detected, the protein level is normal or
slightly elevated, and the glucose level is normal.
PCR is necessary to establish the final diagnosis.
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